2024 CSCO YOUNG | Dr. Biyun Wang: Focusing on Cancer Treatment and the Development of Young Oncologists

2024 CSCO YOUNG | Dr. Biyun Wang: Focusing on Cancer Treatment and the Development of Young Oncologists

On December 28, 2024, the year-end meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO) was successfully held in Shanghai. This event brought together renowned experts and promising young talents from across the country to explore new directions in cancer treatment. Oncology Frontier had the honor of interviewing Dr. Biyun Wang, Chair of the conference and a leading expert at Fudan University Shanghai Cancer Center, who shared key highlights of the conference, insights on the development of young oncologists, the achievements of CSCO YOUNG, and future plans.
ASH 2024 | Dr. Kai Hu: Advancing CAR-T Therapy in Relapsed/Refractory Malignant Lymphoma and Multiple Myeloma

ASH 2024 | Dr. Kai Hu: Advancing CAR-T Therapy in Relapsed/Refractory Malignant Lymphoma and Multiple Myeloma

The 66th American Society of Hematology (ASH) Annual Meeting was held from December 7–10, 2024, in San Diego, USA. As one of the world's largest international academic conferences in the field of hematology, ASH brings together cutting-edge research and the latest drug development data, showcasing the highest level of global hematology research. During this event, Dr. Kai Hu, Director of the Lymphoma and Myeloma Department at Beijing GoBroad Boren Hospital, had multiple studies (abstracts 3079, 3387, and 1745) selected for presentation, focusing on CAR-T therapy in lymphoma and myeloma. Oncology Frontier – Hematology Frontier invited Professor Hu to share in-depth insights and analyses on these studies
2024 Beijing City Annual Lung Cancer Conference | Dr. Yong Song: Advances and Challenges in Anti-Angiogenic Therapy for Lung Cancer

2024 Beijing City Annual Lung Cancer Conference | Dr. Yong Song: Advances and Challenges in Anti-Angiogenic Therapy for Lung Cancer

As the year draws to a close, reflection and progress take center stage. The "2024 Beijing Forbidden City Annual Lung Cancer Conference and the 16th Multidisciplinary Seminar on Advances in Lung Cancer Diagnosis and Treatment," jointly organized by the Beijing Tumor Prevention and Research Association, the China Association of Senior Healthcare, the Beijing Medical Love Public Welfare Foundation, and the Beijing Chen Jumei Public Welfare Foundation, was successfully held on December 13–14, 2024, in Beijing.
ASH 2024 | Dr. Zhihui Li: Prognostic Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Relapsed/Refractory NKTCL Patients

ASH 2024 | Dr. Zhihui Li: Prognostic Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Relapsed/Refractory NKTCL Patients

The 66th American Society of Hematology (ASH) Annual Meeting was held from December 7–10, 2024, in San Diego, USA. As one of the largest global academic events in hematology, it showcased cutting-edge research and the latest drug development data. At this prestigious conference, Dr. Zhihui Li from Beijing GoBroad Boren Hospital (Dr. Tong Wu ’s team) presented an oral abstract (Abstract 599) investigating the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in advanced natural killer/T-cell lymphoma (NKTCL) and analyzing prognostic factors affecting transplantation outcomes. Hematology Frontier  invited Professor Li to provide in-depth insights into this study.
Dr. Rui Xu: New Advances in Surgical Treatment of Breast Cancer and Insights into Integrative Medicine | 2024 Yixian Breast Cancer Conference

Dr. Rui Xu: New Advances in Surgical Treatment of Breast Cancer and Insights into Integrative Medicine | 2024 Yixian Breast Cancer Conference

The 2024 Yixian Breast Cancer Conference and the 2nd China Young Breast Cancer Consensus Conference, held on December 27–28 in Guangzhou, brought together leading experts in breast disease to discuss the latest advancements in treatment and management. The conference also focused on consensus guidelines for diagnosing and treating young breast cancer patients, aiming to improve cure rates and rehabilitation outcomes. At the event, Dr. Rui Xu from the Breast Specialty Hospital of Guangdong Provincial Hospital of Traditional Chinese Medicine shared cutting-edge findings in breast cancer surgery, offering new perspectives for treatment. In an interview with Oncology Frontier, Professor Xu provided an overview of the latest surgical advancements and developments in integrative medicine for breast cancer.
ASH 2024 | Dr. Ruidong Zhang and Dr. Peijing Qi: Analysis of Blinatumomab’s Efficacy and Prospects in Pediatric B-ALL

ASH 2024 | Dr. Ruidong Zhang and Dr. Peijing Qi: Analysis of Blinatumomab’s Efficacy and Prospects in Pediatric B-ALL

The 66th Annual Meeting of the American Society of Hematology (ASH) was held from December 7 to 10, 2024, in San Diego, USA. This global event brought together leading experts in hematology to discuss the latest advancements in the field. At the meeting, the team led by Dr. Ruidong Zhang from Beijing Children’s Hospital，Capital Medical University presented significant findings (Abstract O312) on the treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL), providing fresh insights and possibilities for future therapies. Hematology Frontier invited Dr. Peijing Qi, the study's lead investigator, to provide an in-depth analysis of the research and its implications for clinical practice.